The Pharma Data

NOVEMBER 29, 2020

MDM2 is a key regulator of the tumor suppressor p53 and one of the most potent inhibitors of apoptosis discovered thus far. MDM2 is a key regulator of the tumor suppressor p53 and one of the most potent inhibitors of apoptosis discovered thus far. SUZHOU, China and ROCKVILLE, Md. , 29, 2020 /PRNewswire/ — Ascentage Pharma (6855.HK),

Licensing 40

Licensing Licensing Protein Drugs 40

The Pharma Data

DECEMBER 13, 2020

SHP2 is a critical signaling node and regulator that promotes cancer cell survival and growth through the RAS pathway, playing a key role in the way cancer cells develop resistance to targeted therapies. About RLY-1971. RLY-1971 is a potent small molecule inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2).

Licensing 40

Licensing Licensing Clinical Trials Clinical Trials 40

pharmaphorum

MARCH 19, 2021

Now the Ireland-based firm said that early data from studies shows the system can detect and identify the COVID virus S-Protein in quantities at 40 femtograms per millilitre at close to 100% specificity. It has licensed in a patented breathalyser, the analysts noted. A femtogram is 0.000000000000000001 kilograms.

Contamination 145

Contamination Clinical Trials Clinical Trials Protein 145

XTalks

APRIL 3, 2024

The RBCs in circulation are marked by proteins in the complement system for removal by the spleen and liver. Through its Alexion deal, AstraZeneca is looking to expand into other rare diseases, including various forms of amyloidosis for which it has secured licensing deals and buyouts.

FDA Approval 102

FDA Approval Sales Trials Development 102

XTalks

JANUARY 29, 2021

This is relevant for clinical trials as more regulators require evidence of efficacy in comparison to the standard of care, which is likely to be one of the blockbuster products. Biosimilars are increasingly becoming the standard of care and both have several licensed biosimilar drugs (e.g. Celltrion’s Herceptin biosimilar, Truxima).

Clinical Trials 104

Clinical Trials Clinical Trials Production Trials 104

Drug Discovery World

APRIL 5, 2023

It targets a pathway that cancer cells are highly dependent upon, involving the heat shock factor 1 protein (HSF1). Mechanism of action HSF1 is a transcription factor, meaning that it controls the production of other important proteins in the cell, through its regulation of the process of reading the genetic code stored in DNA.

Drugs 52

Drugs Scientist Clinical Trials Clinical Trials 52

pharmaphorum

JANUARY 6, 2021

RNAi uses small RNA molecules to bind to messenger RNA, which is responsible for synthesising proteins, and either destroy it or recruit other cellular factors that regulate its activity. Several others are in late-stage development, including fitusiran for haemophilia, which Sanofi is developing under license from Alnylam.

Gene Silencing 66

Gene Silencing Gene RNA Contract Manufacturing 66

The Pharma Data

NOVEMBER 17, 2020

Lead Pharma has entered into a collaboration and license agreement with Roche , hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases. . Humans as well as cats and dogs can be affected. .

Immune Response 52

Immune Response Licensing Licensing Sales 52

pharmaphorum

FEBRUARY 19, 2021

billion cumulative doses of its NVX-CoV2373 recombinant protein-based vaccine candidate, which is yet to be approved by regulators. Novavax licensed its NVX-CoV2373 technology to SII with no upfront, milestone or technology transfer payments so that the vaccine can be manufactured and supplied cheaply to poorer countries.

Vaccination 80

Vaccination Vaccine Manufacturing RNA 80

The Pharma Data

OCTOBER 20, 2020

Patent and Trademark Office covering the use of Fatty Acid Binding Protein 5 (FABP5) inhibitors for the treatment of psychological disorders such as anxiety and post-traumatic stress disorder (PTSD). Chronic stress and anxiety disorders, including PTSD, represent significant healthcare and economic burdens worldwide.

Protein 52

Protein Development Research Production 52

pharmaphorum

DECEMBER 21, 2020

But the tragic events of 2020 have meant these companies have become household names as their trailblazing mRNA vaccines became the first to be approved by regulators against the COVID-19 scourge. In this case that is the “spike” protein seen on the surface of the coronavirus that it uses to invade host cells.

Vaccination 111

Vaccination Vaccine Doctors Doctor 111

The Pharma Data

MARCH 14, 2021

This is much lower than would be expected to occur naturally in a general population of this size and is similar across other licensed COVID-19 vaccines. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

Vaccination 52

Vaccination Vaccine Licensing Licensing 52

The Pharma Data

MARCH 1, 2022

This acquisition gives AbbVie access to Syndesi’s portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. The lead molecule, SDI-118, was discovered by UCB before being out-licensed to Syndesi as of 2018. senior vice president, R&D, chief scientific officer, AbbVie.

Protein 52

Protein Licensing Licensing Development 52

pharmaphorum

AUGUST 7, 2020

LRRK2 regulates lysosomes, which play a vital role in cell function by breaking down excess or worn-out cell parts, and can also destroy invading viruses and bacteria. A molecule codenamed DNL151, currently in phase 1 development, has been selected to progress into late stage clinical studies that are expected to begin in 2021.

Bacteria 69

Bacteria Marketing Licensing Licensing 69

XTalks

JANUARY 28, 2022

Immunocore received Breakthrough Device Designation for Kimmtrak from the FDA in February 2021 followed by acceptance of its Biologics License Application (BLA) several months later by both US and European regulators. Kimmtrak is a bispecific protein that contains a soluble T cell receptor fused to an anti-CD3 immune-effector function.

FDA Approval 98

FDA Approval Development Licensing Licensing 98

pharmaphorum

MAY 14, 2021

Cambridge, Massachusetts-based Envisagenics focuses on using AI to analyse errors in RNA splicing, a process in which a precursor form of messenger RNA (mRNA) – which is used as a template for protein synthesis in cells – is transformed into a mature form. It’s not the first partnership for Biogen in the RNA splicing area.

RNA 60

RNA Licensing Licensing Genetics 60

Drug Discovery World

AUGUST 21, 2023

Medications containing semaglutide such as Ozempic, licensed for diabetes, and Wegovy, for weight loss, are being studied to see if they can treat a range of different conditions, including addiction and dementia.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Drugs 52

pharmaphorum

MAY 18, 2021

The vaccine takes the form of SARS-CoV-2 spike protein expressed in virus-like-particles (VLPs), produced in plants that function as mini bioreactors. It has already filed a rolling license application in Canada, and has also picked up fast-track status for the shot from the US FDA.

Immune Response 64

Immune Response Vaccination Vaccine Gene Sequencing 64

pharmaphorum

AUGUST 24, 2020

Just last week, BMS paid $475 million upfront to license Dragonfly Therapeutics’ DF6002, a long-lasting fusion protein that looks like the “tail” (Fc) end of an IL-12 antibody. The rationale behind the drug is that it causes the area around a tumour to become inflammatory, stimulating an immune response against the cancer.

Immune Response 59

Immune Response Antibody Drugs Licensing 59

XTalks

APRIL 26, 2021

It is the world’s first and only licensed malaria vaccine and also the first licensed for use against a human parasitic disease of any kind. The vaccine is protein-based and contains an adjuvant (MM), a component that helps generate a stronger immune response, that was developed by Novavax. Malaria Vaccine Phase II Trial.

Vaccination 105

Vaccination Vaccine Immune Response Trials 105

XTalks

FEBRUARY 8, 2021

They include proteins, monoclonal antibodies and vaccines that are considered to be “ highly similar ” to biological products that have already been approved by the FDA. The regulator allows biosimilars to show slight differences in clinically inactive components of a product. What is a Biosimilar?

Production 78

Production Insulin Branding Generic Drugs 78

The Pharma Data

JANUARY 10, 2021

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / January 11, 2021 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced today that Jean-Paul Kress, M.D., Source link.

Containment 52

Containment Clinical Development Antibody Development 52

The Pharma Data

JANUARY 13, 2021

TNX-1500 is a third generation anti-CD40-ligand mAb that has been designed by protein engineering to decrease Fc?RII CD40-ligand is a protein expressed on the surface of activated T lymphocytes that mediates T cell helper function. antagonist receptor fusion protein. RII, but had other issues, including decreased efficacy 3-5.

Antibody 52

Antibody Development Protein Vaccination 52

Pfizer

AUGUST 15, 2022

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide. Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor. anti-infectives). 07.27.2022.

Drugs 99

Drugs Vaccination Vaccine In-Vitro 99

Pfizer

JANUARY 27, 2023

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. John’s Wort ( hypericum perforatum ) There are limited clinical data available for PAXLOVID.

Marketing 75

Marketing Production Drugs Licensing 75

Pharmaceutical Technology

JANUARY 19, 2023

Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain. The regulator approved Nuvaxovid for use as a primary series in adolescents aged 12 to 17 years in August last year. It has been developed using the company’s recombinant nanoparticle technology.

Vaccination 147

Vaccination Vaccine Immune Response Protein 147

Delveinsight

AUGUST 24, 2021

Ultomiris was considered the first-in-line treatment and the only long-acting C5 complement inhibitor that inhibits C5 protein in the terminal complement cascade, a part of the body’s immune system. HebaBiz Biotech has received a global license for JP001 for anti-tumor indication.

Clinical Trials 96

Clinical Trials Clinical Trials Trials Drugs 96

XTalks

SEPTEMBER 17, 2020

Often, the potential patient pool for a given trial is small and the unmet need is high, incentivizing drugmakers and regulators to find innovative ways to make game-changing therapeutics available to those who need them most. Dietary changes, including restriction of salt and animal protein, are also recommended.

Trials 98

Trials Gene Hormones Clinical Trials 98

pharmaphorum

APRIL 1, 2021

For example, you can simulate what would happen if you inhibited thousands of different proteins in thousands of different cell models.”. There is some pharmaceutical activity with older and well-to-do companies, but they’re more focused on licensing than development.”. So what do they do?

Bioinformatics 123

Bioinformatics Drugs Development Scientist 123

The Pharma Data

JANUARY 18, 2021

OKYO has been developing the chemerin molecule as a promising anti-inflammatory treatment for dry-eye disease (“DED”) licensed from researchers at On Target Therapeutics LLC. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014. LONDON and BOSTON, Jan. Gary S. .

Life Science 40

Life Science Development Sales Drugs 40

The Pharma Data

JULY 23, 2021

The US EUA is temporary and does not take the place of the formal biologics license application (BLA) submission, review and approval process. Ronapreve is a combination of two monoclonal antibodies (also known as REGN10933 and REGN10987, respectively) and was designed to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

Antibody 52

Antibody Medicine Production In-Vitro 52

The Pharma Data

OCTOBER 19, 2020

Pneumococcal serotypes not in the currently licensed conjugate vaccine, such as 22F and 33F, are among the most common serotypes causing invasive pneumococcal disease in parts of the world, including the U.S., Food and Drug Administration before the end of the year, remain on track. among adults 65 years of age or older.

Vaccination 52

Vaccination Vaccine Immune Response Containment 52

Pfizer

JANUARY 27, 2023

Working with collaborators, we have conducted research where the original SARS-CoV-2 virus has been used to express the spike protein from new variants of concern. and global regulators for all antiviral products and are carried out by many companies and academic institutions in the U.S. and around the world.

Research 112

Research Vaccination Vaccine Drugs 112

pharmaphorum

DECEMBER 8, 2020

Its approach involves licensing rights to the antibodies to other pharma companies, rather than bringing its own candidates through development. Bamlanivimab is directed against the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells.

Drugs 111

Drugs Antibody FDA Approval Pharma Companies 111

The Pharma Data

AUGUST 30, 2021

Leqvio works differently from other therapies by preventing the production of the target protein in the liver, increasing hepatic uptake of LDL-C and clearing it from the bloodstream 17. With two doses a year** and effective and sustained LDL-C reduction, Leqvio works as a complement to statins 8,10.

RNA 52

RNA Trials Production Containment 52

The Pharma Data

JULY 27, 2021

Versatile antibody variable domains (UniDab®) derived from UniAb® can be assembled into multi-specific and multivalent therapeutic proteins, surpassing limitations of conventional antibody therapeutics. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures.

Production 52

Production Antibody Sales Manufacturing 52

The Pharma Data

MARCH 22, 2021

Earlier this year, the EMA’s Committee for Medicinal Products for Human Use issued a scientific opinion under Article 5(3) of Regulation 726/2004, supporting the use of casirivimab and imdevimab as a treatment option for patients with confirmed COVID-19.

Antibody 52

Antibody Trials Clinical Trials Clinical Trials 52